批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/01/11 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2022/06/02 |
SUPPL-12(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2021/10/14 |
SUPPL-10(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/10/30 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/08/31 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/05/15 |
ORIG-1(原始申请) |
Approval |
Type 5 - New Formulation or New Manufacturer |
STANDARD
;Orphan
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:BENDAMUSTINE HYDROCHLORIDE 剂型/给药途径:SOLUTION;INTRAVENOUS 规格:100MG/4ML (25MG/ML) 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
205580 |
001 |
NDA |
BELRAPZO |
BENDAMUSTINE HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
100MG/4ML (25MG/ML) |
Prescription |
Yes |
Yes |
AP |
2018/05/15
|
EAGLE PHARMS |
215033 |
001 |
NDA |
BENDAMUSTINE HYDROCHLORIDE |
BENDAMUSTINE HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
100MG/4ML (25MG/ML) |
Prescription |
Yes |
Yes |
AP |
2022/12/07
|
APOTEX |
216078 |
001 |
NDA |
BENDAMUSTINE HYDROCHLORIDE |
BENDAMUSTINE HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
100MG/4ML (25MG/ML) |
Prescription |
Yes |
Yes |
AP |
2022/12/15
|
BAXTER HLTHCARE CORP |